Skip to main content

Table 4 Comparison of sensitivities of FGFR3 mutations, methylation, and combined markers according to stage and grade

From: Promoter hypermethylation of HS3ST2, SEPTIN9 and SLIT2 combined with FGFR3 mutations as a sensitive/specific urinary assay for diagnosis and surveillance in patients with low or high-risk non-muscle-invasive bladder cancer

A. Diagnosis study Primary tumor (n = 167)
 Markers Tumor stage, % (no.) Tumor grade, % (no.)
pTa (n = 126) pT1 (n = 25) CIS (n = 6) Other (n = 10) Low (n = 100) High (n = 67)
  FGFR3
   All mutations 46.0 (58) 28.0 (7) 16.7 (1) 30.0 (3) 53.0 (53) 23.9 (16)
   S249C 69.0 (40) 42.8 (3)    62.2 (33) 62.5 (10)
   Y375C 13.8 (8) 28.6 (2)   33.3 (1) 17.0 (9) 12.5 (2)
   R248C 10.3 (6) 28.6 (2) 100 (1) 33.3 (1) 11.3 (6) 25.0 (4)
   G372C 5.2 (3)     5.7 (3)  
   S249C/R248C 1.7 (1)     1.9 (1)  
   S249C/Y375C     33.3 (1) 1.9 (1)  
   Methylation 90.5 (114) 100 (25) 100 (6) 90.0 (9) 89.0 (89) 100 (67)
   Combined markers 94.4 (119) 100 (25) 100 (6) 90.0 (9) 94.0 (94) 100 (67)
B. Follow-up study Recurrence (n = 72)
 Markers pTa (n = 55) pT1 (n = 11) CIS (n = 2) Other (n = 4) Low (n = 47) High (n = 25)
  FGFR3
   All mutations 43.6 (24) 36.4 (4)   50.0 (2) 46.8 (22) 32.0 (8)
   S249C 58.3 (14) 100 (4)    54.6 (12) 75.0 (6)
   Y375C 20.8 (5)     13.7 (3) 25.0 (2)
   R248C 16.7 (4)    50.0 (1) 22.7 (5)  
   G372C 4.2 (1)     4.5 (1)  
   S249C/R248C     50.0 (1) 4.5 (1)  
   Methylation 89.1 (49) 90.9 (10) 100 (2) 50.0 (2) 85.1 (40) 96.0 (24)
   Combined markers 96.4 (53) 100 (11) 100 (2) 50.0 (2) 93.6 (44) 96.0 (24)